SAN DIEGO, Sept. 4 /PRNewswire/ -- Takeda San Diego announced today that Keith Wilson, Ph.D. has been named president and chief scientific officer (CSO). In this position, he is responsible for overseeing all activities related to Takeda San Diego, Takeda Pharmaceutical Company Limited's U.S.-based drug discovery company.
"Dr. Wilson has been an important part of Takeda San Diego for several years and brings a wealth of scientific excellence to Takeda," said Shigenori Ohkawa, Ph.D., general manager, pharmaceutical research division, Takeda Pharmaceutical Company Limited. "His leadership has been instrumental in focusing the company on drug discovery and building the Takeda San Diego pipeline, and we look forward to his vital contributions in this new role."
Before being named president and CSO at Takeda San Diego, Dr. Wilson served dual roles as vice president of structural biology and vice president of business development. Prior to joining Takeda, he also spent a decade with Vertex Pharmaceuticals co-leading drug discovery programs and significant alliance projects.
Dr. Wilson has formal training in protein X-ray crystallography, and has a doctorate degree in physics from the University of Oregon and a bachelor's degree in physics from Colby College, where he graduated magna cum laude and was awarded the William A. Rogers prize in physics. Dr. Wilson is a contributing author on more than 30 peer-reviewed publications and co-inventor of six issued U.S. patents covering multiple drug candidates.
About Takeda San Diego, Inc.
Takeda San Diego is Takeda's first U.S.-based discovery research
operation. Takeda San Diego achieves an advantage in drug discovery by
leveraging its leading structural biology capabilities to determine the
three dimensional structures of drug targets ahead of competitors and then
uses these structures to efficiently create best-in-class drug candidates
to treat diabetes, cancer, and other important diseases.
|SOURCE Takeda Pharmaceuticals|
Copyright©2007 PR Newswire.
All rights reserved